金彩汇

shouji-banner750X600
long-acting interferon drug product company in Hepatitis and Cytokines

Welcome To Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board (SSE STAR Market) in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. Looking into the future, Amoytop Biotech is especially focusing on CHB (chronic hepatitis B) treatment and will keep advancing the clinical research progress of multiple ongoing pipeline programs aiming to achieve breakthroughs in the clinical cure of CHB.

Research and Innovation

Amoytop Biotech is a leading biopharmaceutical company in China, specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
  • According to company's development strategy, basing on the characteristics, life cycle management and trends...
  • Insisting on constant innovation and development, Amoytop Biotech has created research...​​​​​​​
  • Focusing on major disease treatment and aiming to provide better innovative protein drugs...
  • After over 20 years of innovation and development, Amoytop Biotech has owned many core technology platform...

Specialized In R&D And Production Of Recombinant Protein Products

Prodcut Center

Stay Updated With Our Latest News

网站封面新闻图.png
Approval Granted for Amoytop Biotech's Pegpesen®, a Next-Gen Long-Acting Growth Hormone

On May 29, Amoytop Biotech's independently developed Class 1 new drug, Inpegsomatropin Injection(trade name: Pegpesen®), the world's first Y-shaped 40-kDa PEGylated long-acting growth hormone, officially received market approval from the National Medical Products Administration (NMPA). This drug is

网站封面新闻图.png
AMOYTOP BIOTECH ANNOUNCES CLINICAL COLLABORATION WITH ALIGOS THERAPEUTICS INC

Jul 22, 2024Xiamen, China, July 22, 2024/--Xiamen Amoytop Biotech Co., Ltd. (referred to as Amoytop hereinafter) today announced that it has entered into a clinical trial collaboration agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”).

Contact Details

Emal: international@goodwjj.com; reagent@goodwjj.com
Tel: +86-592-6889106
Hand phone: +86-18060918257
Fax: +86-592-6889110
Address: No. 330 Wengjiao Road, Xinyang Industry Zone of             Haicang, Xiamen, Fujian, P.R.China

Get In Touch

Get In Touch
Facebook
Twitter
LinkedIn
Instagram

WELCOME

Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
Leave a Message
Get In Touch